Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 3/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | GRN | P28799 | 1/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.33 |
| ▸ | CPN1 | P15169 | 2/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4196009 | 1.00 | SLC1A3 (0.36) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL2243927 | 0.83 | GRN (0.40) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL5319747 | 0.83 | GRN (0.40) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL5319748 | 0.83 | GRN (0.40) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL7419744 | 0.83 | LTA4H (0.38) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL19690672 | 0.83 | SLC1A3 (0.43) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL27567892 | 0.82 | EPHX1 (0.39) | METAP2METAP1 | |
| SCHEMBL7384272 | 0.80 | ALDH1A1 (0.40) | LTA4HMETAP2CPB2 | |
| SCHEMBL21197392 | 0.76 | LTA4H (0.44) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL28948924 | 0.76 | LTA4H (0.44) | SLC1A3SLC1A2SLC1A1LTA4HGRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027132-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Alphabeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-01 | — | — | US | claimed |
| US-6960576-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-01 | — | — | US | claimed |
| US-20050113363-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A beta protein production | OLSON RICHARD E (US) | 2005-05-26 | — | — | US | claimed |
| US-20030166636-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-09-04 | — | — | US | claimed |
| CN-1399634-A | Hydroxyalkanoyl aminolactams and related structure as inhibitors of A beta protein production | BRISTOL MYERS SQUIBB PHARMA IN (US) | 2003-02-26 | — | — | CN | claimed |
| EP-1212306-A2 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-12 | — | — | EP | claimed |
| US-20020052360-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-02 | — | — | US | claimed |
| WO-2001019797-A2 | HYDROXYALKANOYL AMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-03-22 | — | — | WO | claimed |
| US-20090111793-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-30 | — | — | US | disclosed |
| US-7423033-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080132482-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-06-05 | — | — | US | disclosed |
| US-7342008-B2 | Containing a benzodiazepine ring; 2-Cyclopentylmethyl-3(S)-hydroxyl-1-oxo-5-phenylpentyl)amino-1-methyl-5-(4-fluoro-phenyl)-2,3-dihydro-1H-1,5-benzodiazepin-2-one; Alzheimer's disease and Down's Syndrome; prevent the formation of neurological deposits of amyloid protein | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070027132-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Alphabeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-01 | — | — | US | disclosed |
| US-6960576-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20030166636-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-09-04 | — | — | US | disclosed |
| CN-1399634-A | Hydroxyalkanoyl aminolactams and related structure as inhibitors of A beta protein production | BRISTOL MYERS SQUIBB PHARMA IN (US) | 2003-02-26 | — | — | CN | disclosed |
| US-6503902-B2 | Treatment of neurological disorders related to beta -amyloid production such as Alzheimer's disease and Down's Syndrome. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | disclosed |
| EP-1212306-A2 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020052360-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-02 | — | — | US | disclosed |
| WO-2001019797-A2 | HYDROXYALKANOYL AMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027132-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Alphabeta protein production | APP, BACE1, APH1A | SLC1A3 1061/4885SLC1A2 804/4885SLC1A1 1153/4885 |
| US-20080132482-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | APP, BACE1, APH1A | SLC1A3 1034/4885SLC1A2 752/4885SLC1A1 1227/4885 |
| US-20030166636-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production | APP, APH1A, APH1B | SLC1A3 787/4885SLC1A2 714/4885SLC1A1 960/4885 |
| US-20020052360-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production | APP, APH1A, BACE1 | SLC1A3 1003/4885SLC1A2 826/4885SLC1A1 1153/4885 |
| US-20050113363-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A beta protein production | APP, BACE1, APH1A | SLC1A3 1034/4885SLC1A2 752/4885SLC1A1 1227/4885 |
| US-20090111793-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | APP, BACE1, APH1A | SLC1A3 1034/4885SLC1A2 752/4885SLC1A1 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.